title: Reply to M.R. Green et al.
authors.affiliation: University Hospital and Zentrum für Klinische Studien, Cologne, Germany.
authors.forename: Oliver A
authors.initials: OA
authors.lastname: Cornely
authors.forename: Mark A
authors.initials: MA
authors.lastname: Miller
authors.forename: Bruno R
authors.initials: BR
authors.lastname: Fantin
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Mullane
authors.forename: Yin
authors.initials: Y
authors.lastname: Kean
authors.forename: Sherwood L
authors.initials: SL
authors.lastname: Gorbach
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000187:drug effects*; D003967:Diarrhea / Q000382:microbiology*; D004761:Enterocolitis, Pseudomembranous / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D014640:Vancomycin